Progress in Alzheimer's and dementia research depends on clinical trials, and eligible participants are needed to move this vital research forward. By participating in U.S. POINTER, you can help to broaden our understanding of risk reduction of cognitive decline.
A wide variety of volunteers, in particular those of diverse backgrounds and under-represented populations, is essential to exploring new approaches and strategies to advance Alzheimer’s research and address scientific gaps.
U.S. POINTER study leadership has been closely monitoring the novel coronavirus (COVID-19) situation. Based on guidance from the Centers for Disease Control and local authorities, we have determined that it is safe to restart in-person research activities.
Please know that we will continue to monitor the situation and will take recommended precautions to protect the health and safety of U.S. POINTER participants and staff.
Not eligible for this study? Learn about other Clinical Trials.
U.S. POINTER add-on studies look deeper into the science of the main study. The neuroimaging ancillary study is the first large-scale investigation of how lifestyle interventions affect biological changes in the brain associated with Alzheimer's and dementia. The sleep ancillary study will examine whether changes in sleep predict changes in overall cognitive function or in specific areas, such as memory.
Contributing to progress in Alzheimer’s research is a highly valuable contribution to a better future for all. If you are not a potential fit for U.S. POINTER or do not live near a U.S. POINTER study site, there are many other important clinical trials underway that need participants.
Learn about studies that are currently recruiting participants by visiting alz.org/TrialMatch and completing a TrialMatch profile online or call 1.800.272.3900 (press 1 for clinical trials). Completing a TrialMatch profile does not commit you to participating in a study.
Whether you are a researcher or potential participant, use this contact information to receive answers to your questions regarding U.S. POINTER.